{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"276.2","value":"382"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"118"}],"units":"Participants"}],"title":"Week 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"70.6","value":"611"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"116"}],"units":"Participants"}],"title":"Week 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"91.4","value":"593"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"114"}],"units":"Participants"}],"title":"Week 9"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"94.9","value":"581"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"}],"units":"Participants"}],"title":"Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"93.2","value":"619"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"111"}],"units":"Participants"}],"title":"Week 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"54.1","value":"639"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"}],"units":"Participants"}],"title":"Week 36"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"90.1","value":"551"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"103"}],"units":"Participants"}],"title":"Week 48"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"58.9","value":"588"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"102"}],"units":"Participants"}],"title":"Week 60"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"96.5","value":"527"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"97"}],"units":"Participants"}],"title":"Week 72"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"91.1","value":"515"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"81"}],"units":"Participants"}],"title":"Week 84"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"106.4","value":"478"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"}],"units":"Participants"}],"title":"Week 96"}],"denoms":[{"counts":[{"groupId":"OG000","value":"124"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received 600 mg oral alectinib twice daily (BID) for 2 years","id":"OG000","title":"Alectinib"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK-evaluable population consisted of all participants who received at least one dose of alectinib and who had at least one post-baseline PK sample available. This population did not include participants from the platinum-based chemotherapy arm, who did not receive alectinib.","reportingStatus":"POSTED","timeFrame":"Predose (2 hours) Week 3 - Week 96","title":"Plasma Concentration of Alectinib","type":"SECONDARY","unitOfMeasure":"ng/mL"}